Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

565
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

740
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
740
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

305
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topic: Evaluation and Treatment of Social Isolation and Loneliness: Evidence-based Recommendations for Stroke and Neurological Rehabilitation.

Current physical medicine and rehabilitation reports·2026
Same author

Concordance Between Bedside and Electronic Detection of Intracranial Pressure Crises: Insights From the Brain Tissue Oxygen Monitoring and Management in Severe Traumatic Brain Injury II Trial.

Critical care medicine·2026
Same author

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Frontiers in immunology·2026
Same author

Gray Matter Morphological Networks are Associated with Neurobiological Features, Cognitive Status and Clinical Recovery in Traumatic Brain Injury.

medRxiv : the preprint server for health sciences·2026
Same author

Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database Analysis.

Advances in therapy·2026
Same author

What Do We Do When the ICP Goes Up?

Neurocritical care·2026
Same journal

Effectiveness of clinical trial recruitment strategies in a safety-net hospital.

Contemporary clinical trials·2026
Same journal

Are older adult research participants representative of the general population? Results from 19 clinical studies at one academic research center.

Contemporary clinical trials·2026
Same journal

Multi-site feasibility of a web-based and telephone navigation intervention to connect lung cancer caregivers in community oncology settings with resources: Protocol for the WF-2301CD Caregiver Oncology Needs Evaluation Tool (CONNECT) trial.

Contemporary clinical trials·2026
Same journal

Rationale and design of a CArdiac rehabilitation program on the prevention of CardioTOXicity in breast Cancer patients undergoing treatment with anthracyclines and/or trastuzumab (CARPTOX-BC) trial: A randomized, active control group, open-label trial.

Contemporary clinical trials·2026
Same journal

Evaluating clinical outcomes of using Undermyfork mobile app with Dexcom G7: Protocol for CGM-Undermyfork randomized controlled trial.

Contemporary clinical trials·2026
Same journal

Outcomes of dyadic recruitment in the promoting re-engagement in meaningful activity (PRIMA) trial.

Contemporary clinical trials·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
07:01

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment

Published on: September 20, 2020

5.0K

Exercise training and cognition in multiple sclerosis: The GET Smart trial protocol.

Charles H Bombardier1, Robert W Motl2, Ralph H B Benedict3

  • 1Department of Rehabilitation Medicine, School of Medicine, University of Washington, Box 359612, Harborview Medical Center, 325 9(th) Ave, Seattle, WA 98104, USA.

Contemporary Clinical Trials
|March 2, 2021
PubMed
Summary
This summary is machine-generated.

Aerobic exercise may improve cognitive processing speed in multiple sclerosis (MS) patients. The GET Smart study is a trial comparing aerobic exercise to stretching and toning for cognitive benefits in MS.

Keywords:
AerobicCognitionExerciseMultiple sclerosisResearch design

More Related Videos

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

17.1K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.1K

Related Experiment Videos

Last Updated: Nov 15, 2025

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
07:01

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment

Published on: September 20, 2020

5.0K
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

17.1K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.1K

Area of Science:

  • Neuroscience
  • Rehabilitation Medicine
  • Clinical Trials

Background:

  • Cognitive impairment affects about 50% of multiple sclerosis (MS) patients.
  • Current treatments offer limited cognitive benefits.
  • Aerobic exercise shows potential for improving cognition in MS.

Purpose of the Study:

  • To investigate the effects of aerobic exercise on cognitive processing speed in adults with MS.
  • To compare aerobic exercise with a stretching and toning control group.
  • To evaluate secondary outcomes including neuropsychological functioning and participant-reported symptoms.

Main Methods:

  • A single-blind, parallel group randomized controlled trial (1:1 ratio).
  • Participants: Nondepressed, ambulatory, non-exercising adults with MS (aged 18-54) with below-average cognitive processing speed.
  • Intervention: 6-month supervised, progressive aerobic exercise program vs. stretching and toning, 3 times/week for 40 minutes.

Main Results:

  • Primary outcome: Significantly greater improvement in cognitive processing speed in the aerobic exercise group compared to the control group at 6 months.
  • Secondary outcomes: Neuropsychological functioning, cardiorespiratory fitness, depression, sleep, and fatigue.
  • Analysis: Intent-to-treat.

Conclusions:

  • Aerobic exercise is a promising intervention for enhancing cognitive function in multiple sclerosis.
  • Findings will guide future research, clinical practice, and patient education.
  • The GET Smart study provides robust evidence on exercise for MS cognition.